Early and long-term responses of intestinal microbiota and metabolites to 131I treatment in differentiated thyroid cancer patients

Abstract

Background

Multiple high doses of ¹³¹I therapy in patients with differentiated thyroid cancer (DTC) might disrupt the balance of gut microbiota and metabolites. This study aimed to investigate the alterations of intestinal bacteria and metabolism over two courses of ¹³¹I therapy, explore the interactions, and construct diagnostic models reflecting enteric microecology based on ¹³¹I therapy.

Methods

A total of 81 patients were recruited for the first ¹³¹I therapy (¹³¹I-1st), among whom 16 received a second course (¹³¹I-2nd) after half a year. Fecal samples were collected 1 day before (Pre-¹³¹I-1st/2nd) and 3 days after (Post-¹³¹I-1st/2nd) ¹³¹I therapy for microbiome (16S rRNA gene sequencing) and metabolomic (LC–MS/MS) analyses.

Results

A total of six microbial genera and 11 fecal metabolites enriched in three pathways were identified to show significant differences between Pre-¹³¹I-1st and other groups throughout the two courses of ¹³¹I treatment. In the Post-¹³¹I-1st group, the beneficial bacteria Bifidobacterium,Lachnoclostridium,uncultured_bacterium_f_Lachnospiraceae, and Lachnospiraceae_UCG004 were abundant and the radiation-sensitive pathways of linoleic acid (LA), arachidonic acid, and tryptophan metabolism were inhibited compared with the Pre-¹³¹I-1st group. Compared with the Pre-¹³¹I-1st group, the Pre-¹³¹I-2nd group exhibited a reduced diversity of flora and differentially expressed metabolites, with a low abundance of beneficial bacteria and dysregulated radiation-sensitive pathways. However, less significant differences in microbiota and metabolites were found between the Pre/Post-¹³¹I-2nd groups compared with those between the Pre/Post-¹³¹I-1st groups. A complex co-occurrence was observed between 6 genera and 11 metabolites, with Lachnoclostridium, Lachnospiraceae_UCG004, Escherichia-Shigella, and LA-related metabolites contributing the most. Furthermore, combined diagnostic models of charactered bacteria and metabolites answered well in the early, long-term, and dose-dependent responses for ¹³¹I therapy.

Conclusions

Different stages of ¹³¹I therapy exert various effects on gut microecology, which play an essential role in regulating radiotoxicity and predicting the therapeutic response.